Join Prof Iain McInnes as he reviews two interesting papers.
Our first paper today by Charles-Schoeman and colleagues compared paraoxonase activity in RA patients treated with tofacitinib, with a focus of PON1 genotypes. Furthermore, the relationship between PON1 genotypes and the risk of MACE and malignancy were also investigated.
In our second paper, Peter Taylor and colleagues evaluated the results of several baricitinib RCTs and real-world evidence studies.
